日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.

对新型蛋白水解靶向嵌合雄激素受体降解剂 Bavdegalutamide (ARV-110) 进行临床前评价

Snyder Lawrence B, Neklesa Taavi K, Willard Ryan R, Gordon Deborah A, Pizzano Jennifer, Vitale Nicholas, Robling Kaitlynn, Dorso Madeline A, Moghrabi Walid, Landrette Sean, Gedrich Richard, Lee Sang Hyun, Taylor Ian C A, Houston John G

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

口服雌激素受体 PROTAC Vepdegestrant (ARV-471) 作为单一疗法以及与 CDK4/6 或 PI3K/mTOR 通路抑制剂联合使用在临床前 ER+ 乳腺癌模型中具有高效性

Sheryl M Gough, John J Flanagan, Jessica Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Debbie Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John Corradi, Katherine Digianantonio, Ieva Drulyte, Ali

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs

开发脂质体系统以增强二价PROTAC的药代动力学特性

Kou, Ponien; Levy, Elizabeth S; Nguyen, An D; Zhang, Donglu; Chen, Shu; Cui, Yusi; Zhang, Xing; Broccatelli, Fabio; Pizzano, Jennifer; Cantley, Jennifer; Bortolon, Elizabeth; Rousseau, Emma; Berlin, Michael; Dragovich, Peter; Sethuraman, Vijay